Monitor the pace and pricing of the ATM share sales. A rapid sale of shares at prices below the current market could signal further bearish sentiment and lead to additional downward pressure on the stock price. The company's ability to manage its cash burn and advance its pipeline will be critical.
Price Chart
Executive Summary
Sutro Biopharma has filed an S-3 shelf registration allowing it to raise up to $300 million in various securities, including a $100 million at-the-market (ATM) offering of common stock through TD Cowen. This signals a need for capital, likely due to its cash burn and recent restructuring. The offering will be dilutive to existing shareholders, with proceeds used for general corporate purposes.
Key Financial Metrics
Key Facts
- S-3 shelf registration filed for up to $300 million in securities (common stock, preferred stock, debt, warrants, etc.).
- Specific $100 million ATM offering of common stock through TD Cowen is part of the shelf registration.
- Company's market cap is $340 million, meaning the $100 million offering represents a 29.4% potential dilution of market cap.
- Company reported a net loss of $144.3 million for the nine months ended September 30, 2025, indicating significant cash burn.
- Proceeds from the offering will be used for general corporate purposes, including R&D and working capital.
Financial Impact
The $100 million offering represents a significant capital raise, potentially diluting existing shareholders by up to 29.4% of the current market cap.
Risk Factors
- Significant dilution for existing shareholders as new shares are sold.
- The need to raise capital suggests ongoing financial pressure and a reliance on the equity markets.
- Management's broad discretion over the use of proceeds introduces uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-120004 |
| Document: d115714dex46.htm | 0001193125-26-120004 |
| Document: d115714dex12.htm | 0001193125-26-120004 |
| CONTEXT: 10-Q (2025-11-06) | 0001193125-25-270036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Aug 12, 2026 7w ago | Press Release | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Apr 22, 2026 23w ago | DEFA14A | $34.83 $31.13 | ▼ −10.62% | ▼ −15.26% | $15.35 (−55.93%) |
Apr 19, 2026 23w ago | Press Release | $34.58 $34.48 | ▼ −0.29% | ▼ −4.49% | $15.35 (−55.61%) |
Mar 23, 2026 27w ago | S-3 | $23.57 $35.53 | ▼ −50.74% | ▼ −41.84% | $15.35 (+34.87%) |
Mar 23, 2026 27w ago | Press Release | $23.57 $35.53 | ▲ +50.74% | ▲ +41.84% | $15.35 (−34.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access